DÄ internationalArchiveReferences
References

Review article

New Oral Anti-Cancer Drugs and Medication Safety

Dtsch Arztebl Int 2019; 116: 775-82. DOI: 10.3238/arztebl.2019.0775

Schlichtig, K; Dürr, P; Dörje, F; Fromm, M F

1.Pasquali S, Hadjinicolaou AV, Chiarion Sileni V, Rossi CR, Mocellin S: Systemic treatments for metastatic cutaneous melanoma. Cochrane Database Syst Rev 2018; 2: CD011123 CrossRef MEDLINE PubMed Central
2.O‘Brien SG, Guilhot F, Larson RA, et al.: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994–1004 CrossRef MEDLINE
3.Coppin C, Le L, Wilt T, Kollmannsberger C: Targeted therapy for advanced renal cell carcinoma (Review). Cochrane Database Syst Rev 2008; 2: CD006017 CrossRef MEDLINE
4.Marin D, Bazeos A, Mahon FX, et al.: Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 2010; 28: 2381–8 CrossRef MEDLINE PubMed Central
5.Noens L, van Lierde MA, De Bock R, et al.: Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 2009; 113: 5401–11 CrossRef MEDLINE
6.Greer JA, Amoyal N, Nisotel L, et al.: A systematic review of adherence to oral antineoplastic therapies. Oncologist 2016; 21: 354–76 CrossRef MEDLINE PubMed Central
7.Deng J, Brar SS, Lesko LJ: To take or not to take with meals? Unraveling issues related to food effects labeling for oral antineoplastic drugs. Clin Pharmacol Drug Dev 2018; 7: 455–64 CrossRef MEDLINE
8.Cascorbi, I: Drug interactions—principles, examples and clinical consequences. Dtsch Arztebl Int 2012; 109: 546–56 CrossRef MEDLINE PubMed Central
9.van Leeuwen RWF, Brundel DHS, Neef C, et al.: Prevalence of potential drug-drug interactions in cancer patients treated with oral anticancer drugs. Br J Cancer 2013; 108: 1071–8 CrossRef MEDLINE PubMed Central
10.Weingart SN, Toro J, Spencer J, et al.: Medication errors involving oral chemotherapy. Cancer 2010; 116: 2455–64 CrossRef MEDLINE
11.Weingart SN, Brown E, Bach PB, et al.: NCCN task force report: oral chemotherapy. J Natl Compr Canc Netw 2008; 6 (Suppl 3): S1–14.
12.Weingart SN, Zhang L, Sweeney M, Hassett M: Chemotherapy medication errors. Lancet Oncol 2018; 19: e191-9 CrossRef
13.Streicher C, Daulange A: Implementation of pharmacist consultations as part of a multidisciplinary consultation program for patients with oral anticancer agent. Eur J Oncol Pharm 2018; 1: e0003 CrossRef
14.Maggiore RJ, Dale W, Gross CP, et al.: Polypharmacy and potentially inappropriate medication use in older adults with cancer undergoing chemotherapy: effect on chemotherapy-related toxicity and hospitalization during treatment. J Am Geriatr Soc 2014; 62: 1505–12 CrossRef MEDLINE PubMed Central
15.Petri H: Arzneimitteltherapiesicherheit: Metabolische Interaktionen der Proteinkinase-Inhibitoren. Dtsch Arztebl 2018; 115: Supplement: Perspektiven der Onkologie, 32–7.
16.Klaeger S, Heinzlmeir S, Wilhelm M, et al.: The target landscape of clinical kinase drugs. Science 2017; 358: eaan4368.
17.Lasala R, Santoleri F, Romagnoli A, Musicco F, Costantini A: Dosage adjustments in pivotal clinical trials with oral targeted therapies in solid tumors conducted in Europe. Eur J Clin Pharmacol 2019; 75: 697–706 CrossRef MEDLINE
18.Liu HB, Wu Y, Lv TF, et al.: Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysis. PLoS One 2013; 8: e55128 CrossRef MEDLINE PubMed Central
19.Petrelli F, Borgonovo K, Cabiddu M, Lonati V, Barni S: Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based meta-analysis of 24 trials. Lung Cancer 2012; 78: 8–15 CrossRef MEDLINE
20.Gutzmer R, Wollenberg A, Ugurel S, Homey B, Ganser A, Kapp A: Cutaneous side effects of new antitumor drugs: clinical features and management. Dtsch Arztebl Int 2012; 109: 133–40 VOLLTEXT
21.Degen A, Alter M, Schenck F, et al.: The hand-foot-syndrome associated with medical tumor therapy—classification and management. J Dtsch Dermatol Ges 2010; 8: 652–61 CrossRef CrossRef MEDLINE
22.Illouz F, Braun D, Briet C, Schweizer U, Rodien P: Endocrine side-effects of anti-cancer drugs: thyroid effects of tyrosine kinase inhibitors. Eur J Endocrinol 2014; 171: R91–9 CrossRef MEDLINE
23.Gutzmer R, Hassel JC, Kahler KC, et al.: Kutane Nebenwirkungen der medikamentösen Tumortherapie mit BRAF- und MEK-Inhibitoren. Hautarzt 2014; 65: 582–9 CrossRef MEDLINE
24.Li J, Gu J: Cardiovascular toxicities with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a meta-analysis of 77 randomized controlled trials. Clin Drug Investig 2018; 38: 1109–23 CrossRef MEDLINE
25.Dobbin SJH, Cameron AC, Petrie MC, Jones RJ, Touyz RM, Lang NN: Toxicity of cancer therapy: what the cardiologist needs to know about angiogenesis inhibitors. Heart 2018; 104: 1995–2002 CrossRef MEDLINE PubMed Central
26.Budolfsen C, Faber J, Grimm D, et al.: Tyrosine kinase inhibitor-induced hypertension: role of hypertension as a biomarker in cancer treatment. Curr Vasc Pharmacol 2019. doi: 10.2174/1570161117666190130165810. [Epub ahead of print] CrossRef MEDLINE
27.Rini BI, Cohen DP, Lu DR, et al.: Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2011; 103: 763–73 CrossRef CrossRef MEDLINE PubMed Central
28.Goldstein D, Rosenberg JE, Figlin RA, et al.: Is change in blood pressure a biomarker of pazopanib and sunitinib efficacy in advanced/metastatic renal cell carcinoma? Eur J Cancer 2016; 53: 96–104 CrossRef MEDLINE
29.Force T, Krause DS, Van Etten RA: Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 2007; 7: 332–44 CrossRef MEDLINE
30.Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC: Epidemiology of cancer-associated venous thrombosis. Blood 2013; 122: 1712–23 CrossRef MEDLINE
31.Shah RR, Morganroth J, Shah DR: Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives. Drug Saf 2013; 36: 491–503 CrossRef MEDLINE
32.Strobach D, Mannell H: Tyrosinkinaseinhibitoren beeinflussen renale Transporter. Was bedeutet das für die klinische Praxis? Krankenhauspharmazie 2019; 40: 70–7.
33.Shah RR: Tyrosine kinase inhibitor-induced Interstitial lung disease: clinical features, diagnostic challenges, and therapeutic dilemmas. Drug Saf 2016; 39: 1073–91 CrossRef MEDLINE
34.Gardner ER, Burger H, van Schaik RH, et al.: Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib. Clin Pharmacol Ther 2006; 80: 192–201 CrossRef MEDLINE
35.Verheijen RB, Yu H, Schellens JHM, Beijnen JH, Steeghs N, Huitema ADR: Practical recommendations for therapeutic drug monitoring of kinase inhibitors in oncology. Clin Pharmacol Ther 2017; 102: 765–76 CrossRef MEDLINE PubMed Central
36.Yu H, Steeghs N, Nijenhuis CM, Schellens JH, Beijnen JH, Huitema AD: Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets. Clin Pharmacokinet 2014; 53: 305–25 CrossRef MEDLINE
37.Williams AM, Baran AM, Casulo C, et al.: Ibrutinib dose adherence and therapeutic efficacy in non-hodgkin lymphoma: a single-center experience. Clin Lymphoma Myeloma Leuk 2018; 19: 41–7 CrossRef MEDLINE
38.Zerillo JA, Goldenberg BA, Kotecha RR, Tewari AK, Jacobson JO, Krzyzanowska MK: Interventions to improve oral chemotherapy safety and quality: a systematic review. JAMA Oncol 2018; 4: 105–17 CrossRef MEDLINE
39.Ribed A, Romero-Jimenez RM, Escudero-Vilaplana V, et al.: Pharmaceutical care program for onco-hematologic outpatients: safety, efficiency and patient satisfaction. Int J Clin Pharm 2016; 38: 280–8 CrossRef MEDLINE
40.Riese C, Weiß B, Borges U, Jr., et al.: Effectiveness of a standardized patient education program on therapy-related side effects and unplanned therapy interruptions in oral cancer therapy: a cluster-randomized controlled trial. Support Care Cancer 2017; 25: 3475–83 CrossRef MEDLINE
e1.Ludwig WD, Schwabe U: Onkologika. In: Schwabe U, Paffrath D, Ludwig WD, Klauber J, (eds.): Arzneiverordnungs-Report 2018. Berlin: Springer 2018; 645–92 CrossRef
e2.Weitschies W, Mehnert W: Arzneimittelwechselwirkungen mit der Nahrung. Einnahme vor, mit oder nach der Mahlzeit? Eschborn: Govi-Verlag Pharmazeutischer Verlag 2014.
e3.Leitlinienprogramm Onkologie: S3-Leitlinie Supportive Therapie bei onkologischen PatientInnen. Langversion 1.1 – April 2017. www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Supportivtherapie/LL_Supportiv_Langversion_1.1.pdf (last accessed on 22 February 2019).
e4.Hesketh PJ, Kris MG, Basch E, et al.: Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2017; 35: 3240–61 CrossRef MEDLINE
e5.Jordan K, Jahn F, Feyer P, et al.: Onkopedia Leitlinie Antiemese bei medikamentöser Tumortherapie. Stand: März 2019. DGHO Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie e.V. www.onkopedia.com/de/onkopedia/guidelines/antiemese-bei-medikamentoeser-tumortherapie/@@view/html/index.html (last accessed on 1 April 2019).
e6.National Comprehensive Cancer Network: NCCN clinical practice guidelines in oncology (NCCN Guidelines®) antiemesis. Version 1.2019. – February 28, 2019. www.nccn.org (last accessed on 26 March 2019).
e7.Leitlinienprogramm Onkologie: S3-Leitlinie zum exokrinen Pankreaskarzinom. Version 1.0 – Oktober 2013. www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Pankreaskarzinom/LL_Pankreas_OL_Langversion.pdf (last accessed on 19 April 2019).
e8.Wörmann B, Driessen C, Einsele H, et al.: Onkopedia Leitlinie Multiples Myelom. Stand: Mai 2018. DGHO Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie e.V. www.onkopedia.com/de/onkopedia/guidelines/multiples-myelom/@@view/html/index.html (last accessed on 19 April 2019).
e9.Hochhaus A, Baerlocher G, Brümmendorf T, et al.: Onkopedia Leitlinie Chronisch Myeloische Leukämie. Stand: Juni 2018. DGHO Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie e.V. www.onkopedia.com/de/onkopedia/guidelines/chronische-myeloische-leukaemie-cml/@@guideline/html/index.html (last accessed on 7 July 2019).
e10.Dürr P, Schlichtig K, Dörje F, Fromm MF: Medication safety in patients treated with new oral antitumor agents: a prospective, randomized investigation on the impact of intensified clinical pharmaceutical/clinical pharmacological care on patient safety and well-being (AMBORA-Study – supported by the German Cancer Aid [70112447]). Abstract. Naunyn-Schmiedeberg‘s Arch Pharmacol 2019; 392: S14.
e11.Neuss MN, Polovich M, McNiff K, et al.: 2013 updated American Society of Clinical Oncology/Oncology Nursing Society chemotherapy administration safety standards including standards for the safe administration and management of oral chemotherapy. J Oncol Pract 2013; 9 (2 Suppl): 5s-13s CrossRef MEDLINE PubMed Central